ORAMED PHARMACEUTICALS INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ORAMED PHARMACEUTICALS INC. (ORMP) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $303.40 thousand for the 137-month period ending 2013-08-31, per its 10-K filed 2013-11-27.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2013-11-27
- ORAMED PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2012-11-30 was $235.87K, a 5509.23% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2011-11-30 was $4.21K.
- ORAMED PHARMACEUTICALS INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2013 was $303.40K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 128 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 137 month |
|---|---|---|---|---|
| 2013-08-31 | $303.40K 10-K · filed 2013-11-27 | $303.40K 10-K · filed 2013-11-27 | ||
| 2012-11-30 | $235.87K 10-Q · filed 2012-12-26 | $235.87K 10-Q · filed 2012-12-26 | ||
| 2011-11-30 | $4.21K 10-Q · filed 2012-12-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |